Breast cancer medication risk

September 29, 2020

New research led by Flinders University has found a link between beta-blockers and survival outcomes in some breast cancer patients.

Beta-blockers, commonly used to manage cardiovascular disease, were negatively associated with survival outcomes in patients with HER2 (Human Epidermal Growth Factor Receptor 2) positive advanced breast cancer, according to a new paper in the Frontiers In Oncology.

Using data collected from 2,777 patients in clinical trials, the study showed worse survival outcomes for patients with HER2 positive ABC group using concomitant beta-blocker, compared to patients not using a BB.

"The research highlights a group of breast cancer patients whose survival outcomes are profoundly poorer," says Professor of Clinical Pharmacology Michael Sorich, director of the Precision Medicine Group at Flinders University's College of Medicine and Public Health

"Given about 20% of breast cancer patients overexpress HER2 - and cardiovascular toxicities are a known complication anti-HER2 therapies - this study importantly identifies a subgroup of patients in which we recommend further investigation to find strategies to improve treatment outcomes."

The research concluded: "Future research should aim to gain a deeper understanding of the effects of beta-blockers on specific breast cancer subtypes, cancer types, and cancer treatments."
-end-
The online article, The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data by ND Modi, JQE Tan, A Rowland, B Koczwara, G Kichenadasse, RA McKinnon, MD Wiese, MJ Sorich and AM Hopkins has been published in Frontiers In Oncology DOI: 10.3389/fonc.2020.01130

Flinders University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.